Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05700903 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Contributions to Hypertension With Androgen Deprivation Therapy

Study acronym: ARCH
StatusTerminated
PhasePhase 4
Started2023-09-20
View on ClinicalTrials.gov ↗
This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.

Amendment history 3 changes detected by DataLookout

2026-09-03
Reclassified as terminated (was completed)
2026-09-03
Trial terminated: Study completed
2026-09-03
Results posted: 2026-09-02
Trial Details
NCT Number NCT05700903
Lead Sponsor University of Colorado, Denver
Conditions Androgen Deprivation Therapy, Prostate Cancer, Hypertension, Autonomic Dysfunction, Renal Disease
Enrollment 10 participants
Start Date 2023-09-20
Primary Completion 2025-07-16 (estimated)
Study Completion 2025-07-16 (estimated)
Updated on ClinicalTrials.gov 2026-09-02